Vinblastine
Tubulin Inhibitor
DB00570
Approved Indication
For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.
6
Targets
0
Resistance Mutations
1
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
The antitumor activity of vinblastine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinblastine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death.
Details
DrugBank ID
DB00570 ↗
Approval Date
2000-07-12
Molecular Weight
810.9741 g/mol
Drug Class
Tubulin Inhibitor
ATC Codes
L01CA01
Synonyms
Vinblastin, Vinblastina, Vinblastine
PubChem
CID: 13342 ↗
ChEMBL
CHEMBL159 ↗
SMILES
[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC
ADMET Profile
Computing properties…
Drug References (DrugBank)